Can a GLP-1 Shrink Your Menopause Belly? What New Science Tells Us
GLP-1 receptor agonists, like semaglutide and tirzepatide, are making headlines not just for dramatic weight loss, but also by proving to help target this hormone-driven transformation.
More from Flow Space
Menopause and Mental Health: Coping with Mood Swings and Anxiety
But can these drugs really help shrink the hormonal belly bulge? What does the latest science say about GLP-1 safety and effectiveness for midlife women? Here's what you need to know.
Menopause belly refers to the increase in abdominal fat that many women experience during and after menopause.
'This shift is driven primarily by hormonal changes, specifically the decrease in estrogen,' Catherine Metzgar, PhD, RD, director of coaching operations at Virta Health, told Flow Space. 'Estrogen plays a key role in regulating body fat distribution, and when levels decline, fat tends to accumulate more viscerally which is around abdominal organs.'
This is a shift from pre-menopause, when fat tends to accumulate more in the hips and thighs.
Other factors that contribute include:
Insulin resistance or insulin sensitivity—associated with increased fat accumulation.
Muscle loss—decreases with age, less muscles results in a slow metabolism.
Stress and sleep issues—increase cortisol levels, which are linked to abdominal fat storage.
These metabolic shifts do have long-term impacts on our health, added Metzgar. Visceral fat is linked to an increased risk for metabolic syndrome, type 2 diabetes and heart disease.
Originally developed for type 2 diabetes, GLP-1 drugs mimic a gut hormone that regulates blood sugar, curbs appetite and slows digestion. This can result in a reduced appetite, improved insulin sensitivity and weight loss, specifically in visceral fat. These effects are especially relevant during menopause, when insulin resistance tends to rise and metabolism slows.
'These GLP-1 medications can help by slowing the time it takes for your stomach to empty and by making you feel fuller longer,' Dr. Brunilda Nazario, chief medical officer at WebMD told Flow Space. 'These drugs can help restore your metabolism, making it easier to lose weight and improve body shape.'
And now a new study has found that GLP-1 agonist, tirzepatide, can help with overall weight loss, as well as reduce deep abdominal fat and improve key cardiometabolic markers.
Physicians from New York-Presbyterian and Weill Cornell Medicine found that a primary concern for women in menopause is weight gain. In order to better understand GLP-1s efficacy for women in midlife, they conducted a secondary analysis of data from the SURMOUNT clinical trial to determine the efficacy of tirzepatide in women in the premenopausal, perimenopausal and postmenopausal stages of life.
What they found was that regardless of reproductive stage, tirzepatide was associated with significant body weight, waist circumference and waist-to-height ratio reductions in women living with obesity or who are overweight.
Tirzepatide, like other GLP-1s, delay gastric emptying and increase feelings of fullness, which help to reduce appetite and, therefore, food intake. These medications also improve insulin response and glucose control, which also supports weight loss.
'These results are not surprising and are consistent with other research evaluating GLP-1 medications and observed weight loss,' says Metzgar. 'Therefore, the findings can likely be applied to other GLP-1 agonists beyond tirzepatide. Even the authors of the study make a similar conclusion.'
The researchers found that tirzepatide worked by targeting the visceral fat in menopausal women in the same way it targets fat for other individuals who used GLP-1 drugs. They also noted that lifestyle changes, like proper diet and exercise, were also an important piece of the equation to ensure optimal results.
'Based on our research, we believe clinicians prescribing tirzepatide can feel more confident recommending the medication to their patients, especially women reporting menopause-related weight gain,' the researchers concluded. 'The data provides reassurance that this medication is effective in the setting of perimenopause and menopause.'
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Los Angeles Times
7 hours ago
- Los Angeles Times
Lawmakers press FDA to target knockoff weight-loss drug
Dozens of lawmakers are urging US health regulators to crack down on the booming market for knockoff weight-loss drugs amid mounting concerns over their potential safety risks. On Friday, a group of more than 80 bipartis an lawmakers asked the US Food and Drug Administration to stop counterfeit and copycat versions of GLP-1 drugs like Wegovy and Zepbound from flooding the market — a problem that emerged over the last year. 'We are concerned about recent reports revealing a surge in illegal and counterfeit anti-obesity medications,' they wrote in a letter to FDA Commissioner Marty Makary. 'Undoubtedly, illegal counterfeit medications pose an increased risk to patient safety with sometimes fatal consequences.' The group — spearheaded by Representatives Richard Hudson of North Carolina and Herb Conaway of New Jersey — asked the agency to ramp up enforcement over illegally imported weight-loss drugs. They suggested issuing warning letters and better monitoring non-compliant online retailers and so-called compounding pharmacies that sell the medicines. The lawmakers also said the FDA should work in tandem with US Customs and Border Patrol agents to stop Chinese entities from shipping unsafe weight-loss drugs into the US. They requested an update on the FDA's efforts by July 30, given the 'urgency' of the situation. A spokesperson for the FDA said the agency will work with the US Department of Health and Human Services to provide a 'complete and thorough' response to the issues raised in the lawmakers' letter. 'Any effort to undermine America's supply of safe medicines is an issue that FDA takes seriously,' the spokesperson said. 'And we are deeply committed to strengthening the oversight of imported products at US ports of entry.' In recent years, the popularity of GLP-1 drugs has led to an explosion of copycats and counterfeits made by companies seeking to capitalize on the hype. State-licensed pharmacies were temporarily allowed to make copies of the drugs during a supply shortage, but are no longer permitted to do so after Novo Nordisk A/S and Eli Lilly & Co. boosted production. Still, some pharmacies have refused to wind down their operations while others have pivoted to selling the drugs in lower doses in order to avoid regulatory scrutiny. Counterfeit drugs are made by unregistered entities typically using illegally imported ingredients. As recently as April, there continue to be instances when counterfeit Ozempic pens covertly enter the drug supply chain undetected. Some patients are also purchasing ingredients directly from online sellers in an attempt to make the drugs themselves at home. In both cases, the medications don't go through the same rigorous approval process as brand-name drugs made by Novo and Lilly. Experts worry the lack of oversight is putting patients at risk. The FDA has said it's aware of hospitalizations potentially linked to the copycat drugs, but that adverse events are likely being underreported. 'We support the bi-partisan call for the FDA to crack down on counterfeit and illegally sold weight-loss drugs,' said a spokesperson for Hims & Hers Health Inc., one of the telehealth firms that sells compounded GLP-1s. 'We appreciate lawmakers' recognition that legitimate compounded medications dispensed by state-regulated pharmacies are not counterfeit. Patient safety must always come first.' Novo and Lilly have discouraged consumers from using compounded and counterfeit products, including suing telehealth firms that sell the copycat versions and working with border agents to seize illegal shipments. Under the Biden administration, the companies repeatedly urged the FDA to take action, but the agency mostly limited its actions to issuing consumer warnings — even as its top drug official publicly acknowledged safety concerns. Under the Trump administration, the HHS has also focused more heavily on other issues, such as banning food dyes and examining vaccine schedules. Meanwhile, lawmakers are ramping up their calls for action. State attorneys and other lawmakers have sent letters to the FDA and Federal Trade Commission advocating for greater transparency around the treatments and more scrutiny around marketing practices. Muller writes for Bloomberg.
Yahoo
14 hours ago
- Yahoo
Semaglutide improves brain-related injury patients' outcomes
GLP-1R agonist semaglutide, also known as Ozempic or Wegovy, has been making headlines for its potential in its original market - the treatment of Type 2 diabetes - for its weight loss effects and benefits in other metabolic disorders, and for its possible expansions into new therapeutic areas. Most recently, results from different studies have suggested that semaglutide may improve patient outcomes following brain haemorrhage or stroke. GlobalData estimates that semaglutide's benefits may be connected to a reduction of inflammation in the body and brain. As mentioned in GlobalData's report: GLP-1R Agonist - Label Expansions/Drug Repurposing: Market Overview, Ozempic is currently in Phase II trials for acute ischaemic stroke. Other GLP-1R agonists and combination therapies are in clinical development for other neurological conditions, and many academic studies are currently focusing on the potential use of GLP-1R agonists in stroke to reduce complications and the risk of recurrence altogether. In July 2025, new results have emerged from three studies investigating the use of semaglutide in stroke and brain haemorrhage patients. A study by the University of Wisconsin-Madison revealed that the chance of surviving after a stroke was higher in patients on semaglutide, and death from stroke was more frequent in the patient group not on a GLP-1R agonist. Another study by the same university examining a US nationwide sample of hospital records found an association between the use of GLP-1R agonists and a reduction in stroke complications. A third study by the University of Texas Medical Branch in Galveston suggested that semaglutide use was linked to a reduced risk of side effects, seizures, future recurrence and death after brain haemorrhage and stroke. The SELECT trial has demonstrated a clear cardiovascular protection associated with semaglutide use, which could explain its benefits in stroke patients. Furthermore, the occurrence of stroke is linked to metabolic health, inflammation and obesity, so an improvement in these factors can benefit patients likely to experience a stroke or who have done so in the past. According to key opinion leaders interviewed by GlobalData, the potential of GLP-1R agonists in brain diseases seems to be based on their anti-inflammatory action. Indeed, GLP-1R agonists are known to improve insulin sensitivity and reduce insulin resistance, and it seems that this translates to the brain too, as these molecules can cross the blood-brain barrier. Cerebrovascular conditions such as stroke and brain hemorrhage appear to benefit from both the cardiovascular benefits and cerebral anti-inflammatory health benefits associated with GLP-1R agonists' use, on top of the improvement in overall health. Therefore, GLP-1R agonists may successfully penetrate not one but multiple neurological diseases markets, if their effects are proven to be significant and worth the cost of these medicines. "Semaglutide improves brain-related injury patients' outcomes" was originally created and published by Clinical Trials Arena, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Medscape
19 hours ago
- Medscape
GLP-1s Only Opening Act: Experts Unveil Diet-Exercise Guide
The weight loss seen with GLP-1 receptor agonists is only half the story. Long-term success hinges on integrating medication with individualized nutrition and physical activity counseling, a trio of experts remind clinicians in a new paper. GLP-1 medications and dual receptor agonist medications are 'very effective in terms of weight loss, achieving about 20% weight loss or more,' JoAnn Manson, MD, MPH, professor of medicine, Harvard Medical School and Brigham and Women's Hospital, both in Boston, told Medscape Medical News . However, the loss of muscle mass and lean body mass is also 'quite common, sometimes accounting for 25% or more of the total weight loss.' Lifestyle factors are 'crucial' to optimize outcomes for patients on GLP-1 medications, Manson said. She and her coauthors offered advice on integrating diet and physical activity and managing potential side effects in patients with obesity starting a GLP-1 medication in a brief two-page 'Clinical Insights' article in JAMA Internal Medicine. There is also companion 'Patient Page.' Monitor Weight Loss Clinicians should track weight monthly during GLP-1 dose escalation and at least quarterly thereafter, intervening if patients lose too little or too much weight, the authors advised. For those with < 5% weight loss after 12-16 weeks, options include continuing standard dose escalation and documenting progress, given that standard titration periods (at least 17 weeks) may not work for all individuals; checking for missed doses and adjust dose titration as needed to maximize adherence; or switching to an alternative GLP-1 drug if the maximum tolerated dose is not effective, they said. It's also important to monitor for excessive weight loss, the authors said. Indications that weight loss may be excessive or harming overall health include a BMI < 18.5, anorexia (consuming < 800 calories/d), or very low protein intake. In a patient with excessive weight loss, it's important to rule out secondary causes such as eating or endocrine disorders or malignant tumors, assess for correlated harms including nutrient deficiencies and hormonal imbalances, assess psychological function with referrals to specialists as needed, and consider dose reduction or stopping the medication temporarily, the author advised. Assess Diet, Manage Nutrient Intake If available, patients should see a registered dietitian initially, with follow-up visits every 2-3 months during dose escalation. If this is not feasible, clinicians can administer the Rapid Eating Assessment for Participants-Shortened, a brief nutritional assessment tool. The authors emphasized that nutrient quality is more important than rigid calorie counting. However, patients may also benefit from periodic tracking of their food and fluid intake through smartphone applications, manual food logs or taking photos of their food to help guide dietary adjustments. For patients comfortable with tracking their calories, target calorie ranges should be individualized based on weight goals and activity level. To minimize muscle loss, patients should be advised to maintain adequate protein intake of 60-75 g/d (1.0-1.5 g/kg; > 1.5 g/kg for older or post-bariatric surgery patients) and engage in structured physical activity (aerobic and strength training). To maintain energy balance, smaller, nutrient-dense meals rather than calorie restriction is advised. Whole grains for satiety and sustained energy and healthy fats to support fat-soluble vitamin absorption and reduce cholestasis are recommended. Manson noted that 'gastrointestinal symptoms — such as nausea, constipation, and reflux — can limit the use of these medications, lead to drug discontinuation, and subsequently results in weight regain.' To help ward off constipation, patients should be advised to increase fiber intake and take in more than 2-3 L of fluid a day and use over-the-counter laxatives if needed. For nausea, they should avoid fried foods and carbonated drinks. For reflux, eating smaller portions, not lying down for 2-3 hours after meals and limiting high-fat and irritating spices may help. Because appetite suppression induced by GLP-1 medications can unmask hidden micronutrient deficiencies, clinicians could consider assessment of vitamin D, iron, B-vitamins, and other micronutrients and add a multivitamin when intake is chronically low, the authors said. Physical Activity: Start Slow and Add-On The authors recommend a three-step approach to counseling patients on physical activity. First, introduce regular movement gradually and work up to 150 minutes of moderate (or 75 min of vigorous) activity weekly. Second, incorporate resistance training, aiming for 60-90 min/wk. Third, maintain 30-60 minutes per day of aerobic exercise combined with resistance training two to three times per week for optimal long-term weight and metabolic outcomes. Balance and mobility training for older adults can be especially helpful, the author said. Clinicians may also consider assessing muscle strength and function, such as the grip strength or 6-minute walk test, the authors said. Weight Regain Patients who discontinue GLP-1 therapy may regain weight and this should be discussed with patients at the start of treatment, the authors said. Specifically, in randomized controlled trials, weight rebound of roughly 7%-12% has been observed within 1 year of stopping GLP-1 therapy and that lifestyle habits put in place early will be the main defense if dose reductions or discontinuation are attempted. The authors noted that all patients will reach a weight-loss plateau, but weight maintenance protocols for GLP-1 drugs have yet to be established. 'Clinicians should base treatment decisions on the premise that obesity is a chronic condition typically requiring long-term management, similar to hypertension,' they advised. When a decision to taper the medication is made, options include reducing the dose or frequency of injections or tapering off treatment completely with progressively less monitoring (weekly to biweekly, followed by monthly, then quarterly) over at least 20 weeks. 'Clinicians should continue to assess weight, metabolic health, diet and activity levels, appetite, sleep patterns, mood changes, and muscle strength. Medication reinitiation or dose increase should be considered if weight regain exceeds 5%,' they advised. Manson told Medscape Medical News she hopes this information will be a 'good resource that will result in better care for patients on GLP-1 medications and better outcomes.'
